{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:19:08Z","timestamp":1778545148289,"version":"3.51.4"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA036727"],"award-info":[{"award-number":["CA036727"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA212413"],"award-info":[{"award-number":["R01CA212413"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM134955"],"award-info":[{"award-number":["R35GM134955"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA230255"],"award-info":[{"award-number":["CA230255"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02709-1","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:02:57Z","timestamp":1778544177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SSTNIV, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progression"],"prefix":"10.1038","volume":"11","author":[{"given":"Oisun","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DeannaLee M.","family":"Beauvais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavril L.","family":"Ibaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin C.","family":"Wooldrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Flietner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan C.","family":"Rapraeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2709_CR1","doi-asserted-by":"crossref","unstructured":"Solimando, A. G., Da Via, M. C., Bolli, N. & Steinbrunn, T. The route of the malignant plasma cell in its survival niche: exploring \u201cmultiple myelomas\u201d. Cancers 14, 3271 (2022).","DOI":"10.3390\/cancers14133271"},{"key":"2709_CR2","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516\u20132520 (2008).","journal-title":"Blood"},{"key":"2709_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s40265-017-0833-y","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy, S. M. Pomalidomide: a review in relapsed and refractory multiple myeloma. Drugs 77, 1897\u20131908 (2017).","journal-title":"Drugs"},{"issue":"Suppl 1","key":"2709_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s12032-010-9442-2","volume":"27","author":"JP Laubach","year":"2010","unstructured":"Laubach, J. P., Richardson, P. G. & Anderson, K. C. The evolution and impact of therapy in multiple myeloma. Med Oncol. 27(Suppl 1), S1\u2013S6 (2010).","journal-title":"Med Oncol."},{"key":"2709_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00277-002-0437-8","volume":"81","author":"RD Sanderson","year":"2002","unstructured":"Sanderson, R. D. & Borset, M. Syndecan-1 in B lymphoid malignancies. Ann. Hematol. 81, 125\u2013135 (2002).","journal-title":"Ann. Hematol."},{"key":"2709_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2020008188","volume":"137","author":"Z Ren","year":"2021","unstructured":"Ren, Z., Spaargaren, M. & Pals, S. T. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis. Blood 137, 1713\u20131718 (2021).","journal-title":"Blood"},{"key":"2709_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1365-2141.2005.05647.x","volume":"130","author":"R Lovell","year":"2005","unstructured":"Lovell, R. et al. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. Br. J. Haematol. 130, 542\u2013548 (2005).","journal-title":"Br. J. Haematol."},{"key":"2709_CR8","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1182\/blood-2009-07-234757","volume":"115","author":"A Purushothaman","year":"2010","unstructured":"Purushothaman, A. et al. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 2449\u20132457 (2010).","journal-title":"Blood"},{"key":"2709_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1369\/0022155420937087","volume":"68","author":"S Rangarajan","year":"2020","unstructured":"Rangarajan, S. et al. Heparanase-enhanced shedding of syndecan-1 and its role in driving disease pathogenesis and progression. J. Histochem. Cytochem. 68, 823\u2013840 (2020).","journal-title":"J. Histochem. Cytochem."},{"key":"2709_CR10","doi-asserted-by":"publisher","first-page":"13326","DOI":"10.1074\/jbc.M611259200","volume":"282","author":"Y Yang","year":"2007","unstructured":"Yang, Y. et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J. Biol. Chem. 282, 13326\u201313333 (2007).","journal-title":"J. Biol. Chem."},{"key":"2709_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-3-030-34521-1_12","volume":"1221","author":"A Purushothaman","year":"2020","unstructured":"Purushothaman, A. & Sanderson, R. D. Heparanase: a dynamic promoter of myeloma progression. Adv. Exp. Med. Biol. 1221, 331\u2013349 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2709_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00277-014-2211-0","volume":"94","author":"G An","year":"2015","unstructured":"An, G. et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann. Hematol. 94, 257\u2013264 (2015).","journal-title":"Ann. Hematol."},{"key":"2709_CR13","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","volume":"103","author":"W Matsui","year":"2004","unstructured":"Matsui, W. et al. Characterization of clonogenic multiple myeloma cells. Blood 103, 2332\u20132336 (2004).","journal-title":"Blood"},{"key":"2709_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood.V95.2.388","volume":"95","author":"C Seidel","year":"2000","unstructured":"Seidel, C. et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95, 388\u2013392 (2000).","journal-title":"Blood"},{"key":"2709_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1046\/j.1365-2141.1997.3893203.x","volume":"99","author":"MV Dhodapkar","year":"1997","unstructured":"Dhodapkar, M. V. et al. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br. J. Haematol. 99, 368\u2013371 (1997).","journal-title":"Br. J. Haematol."},{"key":"2709_CR16","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-16-0232","volume":"76","author":"DM Beauvais","year":"2016","unstructured":"Beauvais, D. M., Jung, O., Yang, Y., Sanderson, R. D. & Rapraeger, A. C. Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by SynstatinIGF1R inhibits tumor growth. Cancer Res. 76, 4981\u20134993 (2016).","journal-title":"Cancer Res."},{"key":"2709_CR17","doi-asserted-by":"publisher","first-page":"26085","DOI":"10.1074\/jbc.M109.018473","volume":"284","author":"YB Khotskaya","year":"2009","unstructured":"Khotskaya, Y. B. et al. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J. Biol. Chem. 284, 26085\u201326095 (2009).","journal-title":"J. Biol. Chem."},{"key":"2709_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.5","volume":"5","author":"O Jung","year":"2016","unstructured":"Jung, O. et al. Heparanase-induced shedding of syndecan-1\/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis 5, e202 (2016).","journal-title":"Oncogenesis"},{"key":"2709_CR19","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1111\/febs.12160","volume":"280","author":"AC Rapraeger","year":"2013","unstructured":"Rapraeger, A. C. Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-alphavbeta3 integrin complex in tumorigenesis and angiogenesis. FEBS J. 280, 2207\u20132215 (2013).","journal-title":"FEBS J."},{"key":"2709_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1084\/jem.20081278","volume":"206","author":"DM Beauvais","year":"2009","unstructured":"Beauvais, D. M., Ell, B. J., McWhorter, A. R. & Rapraeger, A. C. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J. Exp. Med. 206, 691\u2013705 (2009).","journal-title":"J. Exp. Med."},{"key":"2709_CR21","first-page":"917","volume":"23","author":"T Kusumoto","year":"2010","unstructured":"Kusumoto, T. et al. Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol. Rep. 23, 917\u2013925 (2010).","journal-title":"Oncol. Rep."},{"key":"2709_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13045-016-0380-0","volume":"10","author":"K Schonfeld","year":"2017","unstructured":"Schonfeld, K. et al. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. J. Hematol. Oncol. 10, 13 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"2709_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00378-z","volume":"10","author":"T Yu","year":"2020","unstructured":"Yu, T. et al. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 10, 110 (2020).","journal-title":"Blood Cancer J."},{"key":"2709_CR24","first-page":"209","volume":"4","author":"WP Sun","year":"2007","unstructured":"Sun, W. P. et al. A novel anti-human syndecan-1 (CD138) monoclonal antibody 4B3: characterization and application. Cell. Mol. Immunol. 4, 209\u2013214 (2007).","journal-title":"Cell. Mol. Immunol."},{"key":"2709_CR25","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.18632\/oncotarget.26792","volume":"10","author":"C Sun","year":"2019","unstructured":"Sun, C. et al. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Oncotarget 10, 2369\u20132383 (2019).","journal-title":"Oncotarget"},{"key":"2709_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","volume":"8","author":"H Jiang","year":"2014","unstructured":"Jiang, H. et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol. Oncol. 8, 297\u2013310 (2014).","journal-title":"Mol. Oncol."},{"key":"2709_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2141.2011.08850.x","volume":"155","author":"J Bae","year":"2011","unstructured":"Bae, J., Tai, Y. T., Anderson, K. C. & Munshi, N. C. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br. J. Haematol. 155, 349\u2013361 (2011).","journal-title":"Br. J. Haematol."},{"key":"2709_CR28","doi-asserted-by":"crossref","unstructured":"Jung, O., Beauvais, D. M., Adams, K. M. & Rapraeger, A. C. VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1. J. Cell Sci. 132, jcs232645 (2019).","DOI":"10.1242\/jcs.232645"},{"key":"2709_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2020007156","volume":"137","author":"Z Wen","year":"2021","unstructured":"Wen, Z. et al. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood 137, 61\u201374 (2021).","journal-title":"Blood"},{"key":"2709_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14114-z","volume":"12","author":"E Flietner","year":"2022","unstructured":"Flietner, E. et al. Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model. Sci. Rep. 12, 10616 (2022).","journal-title":"Sci. Rep."},{"key":"2709_CR31","doi-asserted-by":"publisher","first-page":"14019","DOI":"10.1016\/S0021-9258(19)49672-5","volume":"267","author":"SP Massia","year":"1992","unstructured":"Massia, S. P. & Hubbell, J. A. Vascular endothelial cell adhesion and spreading promoted by the peptide REDV of the IIICS region of plasma fibronectin is mediated by integrin alpha 4 beta 1. J. Biol. Chem. 267, 14019\u201314026 (1992).","journal-title":"J. Biol. Chem."},{"key":"2709_CR32","doi-asserted-by":"publisher","first-page":"26103","DOI":"10.1074\/jbc.M115.679084","volume":"290","author":"H Wang","year":"2015","unstructured":"Wang, H., Jin, H. & Rapraeger, A. C. Syndecan-1 and syndecan-4 capture epidermal growth factor receptor family members and the alpha3beta1 integrin via binding sites in their ectodomains: novel synstatins prevent kinase capture and inhibit alpha6beta4-integrin-dependent epithelial cell motility. J. Biol. Chem. 290, 26103\u201326113 (2015).","journal-title":"J. Biol. Chem."},{"key":"2709_CR33","doi-asserted-by":"publisher","first-page":"13569","DOI":"10.1074\/jbc.M110.102137","volume":"285","author":"H Wang","year":"2010","unstructured":"Wang, H., Leavitt, L., Ramaswamy, R. & Rapraeger, A. C. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation. J. Biol. Chem. 285, 13569\u201313579 (2010).","journal-title":"J. Biol. Chem."},{"key":"2709_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12985-025-02923-3","volume":"22","author":"R Ahani","year":"2025","unstructured":"Ahani, R. et al. Enhancement of lentiviral vectors gene delivery against VEGFR2 expressing cells by co-display of the binding and fusogenic moieties: a two molecules targeting approach. Virol. J. 22, 300 (2025).","journal-title":"Virol. J."},{"key":"2709_CR35","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1593\/neo.04631","volume":"7","author":"S Ran","year":"2005","unstructured":"Ran, S., Mohamedali, K. A., Luster, T. A., Thorpe, P. E. & Rosenblum, M. G. The vascular-ablative agent VEGF(121)\/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia 7, 486\u2013496 (2005).","journal-title":"Neoplasia"},{"key":"2709_CR36","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1080\/10428194.2020.1751840","volume":"61","author":"Y Gu","year":"2020","unstructured":"Gu, Y. et al. Low absolute CD4(+) T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma. Leuk. Lymphoma 61, 1869\u20131876 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"2709_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J. Hematol. Oncol. 9, 116 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"2709_CR38","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","volume":"114","author":"Y Zheng","year":"2009","unstructured":"Zheng, Y. et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114, 3625\u20133628 (2009).","journal-title":"Blood"},{"key":"2709_CR39","doi-asserted-by":"publisher","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","volume":"7","author":"KR Muthu Raja","year":"2012","unstructured":"Muthu Raja, K. R. et al. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS ONE 7, e47077 (2012).","journal-title":"PLoS ONE"},{"key":"2709_CR40","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","volume":"144","author":"S Feyler","year":"2009","unstructured":"Feyler, S. et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br. J. Haematol. 144, 686\u2013695 (2009).","journal-title":"Br. J. Haematol."},{"key":"2709_CR41","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","volume":"107","author":"M Beyer","year":"2006","unstructured":"Beyer, M. et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 107, 3940\u20133949 (2006).","journal-title":"Blood"},{"key":"2709_CR42","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/bjc.2011.575","volume":"106","author":"K Giannopoulos","year":"2012","unstructured":"Giannopoulos, K., Kaminska, W., Hus, I. & Dmoszynska, A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br. J. Cancer 106, 546\u2013552 (2012).","journal-title":"Br. J. Cancer"},{"key":"2709_CR43","doi-asserted-by":"crossref","unstructured":"Hadjiaggelidou, C. & Katodritou, E. Regulatory T-cells and multiple myeloma: implications in tumor immune biology and treatment. J. Clin. Med. 10, 4588 (2021).","DOI":"10.3390\/jcm10194588"},{"key":"2709_CR44","doi-asserted-by":"crossref","unstructured":"Sun, J. et al. Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. J. Immunother. Cancer 10, e003975 (2022).","DOI":"10.1136\/jitc-2021-003975"},{"key":"2709_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40425-019-0622-0","volume":"7","author":"B Benner","year":"2019","unstructured":"Benner, B. et al. Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. J. Immunother. Cancer 7, 140 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2709_CR46","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-22-1769","volume":"83","author":"L Yao","year":"2023","unstructured":"Yao, L. et al. Single-cell discovery and multiomic characterization of therapeutic targets in multiple myeloma. Cancer Res 83, 1214\u20131233 (2023).","journal-title":"Cancer Res"},{"key":"2709_CR47","doi-asserted-by":"publisher","first-page":"1352946","DOI":"10.3389\/fimmu.2024.1352946","volume":"15","author":"M Luo","year":"2024","unstructured":"Luo, M., Zhao, F., Cheng, H., Su, M. & Wang, Y. Macrophage polarization: an important role in inflammatory diseases. Front. Immunol. 15, 1352946 (2024).","journal-title":"Front. Immunol."},{"key":"2709_CR48","doi-asserted-by":"publisher","first-page":"520","DOI":"10.7150\/ijbs.8879","volume":"10","author":"YC Liu","year":"2014","unstructured":"Liu, Y. C., Zou, X. B., Chai, Y. F. & Yao, Y. M. Macrophage polarization in inflammatory diseases. Int. J. Biol. Sci. 10, 520\u2013529 (2014).","journal-title":"Int. J. Biol. Sci."},{"key":"2709_CR49","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41388-023-02684-9","volume":"42","author":"E Flietner","year":"2023","unstructured":"Flietner, E. et al. Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses. Oncogene 42, 1751\u20131762 (2023).","journal-title":"Oncogene"},{"key":"2709_CR50","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/toxics3030294","volume":"3","author":"C Meregalli","year":"2015","unstructured":"Meregalli, C. An overview of bortezomib-induced neurotoxicity. Toxics 3, 294\u2013303 (2015).","journal-title":"Toxics"},{"key":"2709_CR51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.expneurol.2010.02.006","volume":"223","author":"J Bruna","year":"2010","unstructured":"Bruna, J. et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp. Neurol. 223, 599\u2013608 (2010).","journal-title":"Exp. Neurol."},{"key":"2709_CR52","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano, Y. et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263, 160\u2013172 (2015).","journal-title":"Immunol. Rev."},{"key":"2709_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77450-y","volume":"10","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment. Sci. Rep. 10, 20508 (2020).","journal-title":"Sci. Rep."},{"key":"2709_CR54","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2011-04-347484","volume":"120","author":"I Bruns","year":"2012","unstructured":"Bruns, I. et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood 120, 2620\u20132630 (2012).","journal-title":"Blood"},{"key":"2709_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.793040","volume":"8","author":"I Laurenzana","year":"2021","unstructured":"Laurenzana, I. et al. Multiple myeloma-derived extracellular vesicles impair normal hematopoiesis by acting on hematopoietic stem and progenitor cells. Front. Med. 8, 793040 (2021).","journal-title":"Front. Med."},{"key":"2709_CR56","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar, S. V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. 95, 548\u2013567 (2020).","journal-title":"Am. J. Hematol."},{"key":"2709_CR57","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5455\/OVJ.2023.v13.i2.12","volume":"13","author":"V Turinelli","year":"2023","unstructured":"Turinelli, V., Rossi, G. & Gavazza, A. Retrospective study of 613 canine cytologically normal bone marrows associated to altered hemograms: description, possible interpretation, and review of the principal physiological hematopoietic mechanisms. Open Vet. J. 13, 233\u2013240 (2023).","journal-title":"Open Vet. J."},{"key":"2709_CR58","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ajh.24291","volume":"91","author":"A Bouchnita","year":"2016","unstructured":"Bouchnita, A., Eymard, N., Moyo, T. K., Koury, M. J. & Volpert, V. Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis. Am. J. Hematol. 91, 371\u2013378 (2016).","journal-title":"Am. J. Hematol."},{"key":"2709_CR59","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nbt0502-473","volume":"20","author":"S Fredriksson","year":"2002","unstructured":"Fredriksson, S. et al. Protein detection using proximity-dependent DNA ligation assays. Nat. Biotechnol. 20, 473\u2013477 (2002).","journal-title":"Nat. Biotechnol."},{"key":"2709_CR60","doi-asserted-by":"publisher","first-page":"362","DOI":"10.5858\/arpa.2017-0480-OA","volume":"143","author":"W Su","year":"2019","unstructured":"Su, W., Yang, L., Luo, X., Chen, M. & Liu, J. Elimination of autofluorescence in archival formaldehyde-fixed, paraffin-embedded bone marrow biopsies. Arch. Pathol. Lab. Med. 143, 362\u2013369 (2019).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"2709_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blade","year":"2022","unstructured":"Blade, J. et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 12, 45 (2022).","journal-title":"Blood Cancer J."},{"key":"2709_CR62","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","volume":"127","author":"C Touzeau","year":"2016","unstructured":"Touzeau, C. & Moreau, P. How I treat extramedullary myeloma. Blood 127, 971\u2013976 (2016).","journal-title":"Blood"},{"key":"2709_CR63","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/bmt.2017.165","volume":"52","author":"L Kumar","year":"2017","unstructured":"Kumar, L. et al. Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transplant. 52, 1473\u20131475 (2017).","journal-title":"Bone Marrow Transplant."},{"key":"2709_CR64","doi-asserted-by":"publisher","first-page":"8203","DOI":"10.2174\/0929867328666210720143721","volume":"28","author":"S Dallavalasa","year":"2021","unstructured":"Dallavalasa, S. et al. The role of tumor associated macrophages (TAMs) in cancer progression, chemoresistance, angiogenesis and metastasis\u2014current status. Curr. Med. Chem. 28, 8203\u20138236 (2021).","journal-title":"Curr. Med. Chem."},{"key":"2709_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106709","volume":"110","author":"M Sun","year":"2021","unstructured":"Sun, M. et al. Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma. Leuk. Res. 110, 106709 (2021).","journal-title":"Leuk. Res."},{"key":"2709_CR66","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.3390\/curroncol30070455","volume":"30","author":"E Cencini","year":"2023","unstructured":"Cencini, E. et al. Tumor-associated macrophages in multiple myeloma: key role in disease biology and potential therapeutic implications. Curr. Oncol. 30, 6111\u20136133 (2023).","journal-title":"Curr. Oncol."},{"key":"2709_CR67","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00277-012-1652-6","volume":"92","author":"E Suyani","year":"2013","unstructured":"Suyani, E. et al. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann. Hematol. 92, 669\u2013677 (2013).","journal-title":"Ann. Hematol."},{"key":"2709_CR68","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/leu.2015.191","volume":"30","author":"S Panchabhai","year":"2016","unstructured":"Panchabhai, S. et al. Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. Leukemia 30, 951\u2013954 (2016).","journal-title":"Leukemia"},{"key":"2709_CR69","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1002\/cam4.4814","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1\/PD-L1 pathway in multiple myeloma. Cancer Med. 11, 4838\u20134848 (2022).","journal-title":"Cancer Med."},{"key":"2709_CR70","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.7150\/jca.30102","volume":"10","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. J. Cancer 10, 3239\u20133245 (2019).","journal-title":"J. Cancer"},{"key":"2709_CR71","first-page":"299","volume":"62","author":"Y Kawano","year":"2021","unstructured":"Kawano, Y. The role of regulatory T cells in multiple myeloma progression. Rinsho Ketsueki 62, 299\u2013304 (2021).","journal-title":"Rinsho Ketsueki"},{"key":"2709_CR72","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41420-023-01765-8","volume":"9","author":"H Chen","year":"2023","unstructured":"Chen, H., Wang, X., Wang, Y. & Chang, X. What happens to regulatory T cells in multiple myeloma. Cell Death Discov. 9, 468 (2023).","journal-title":"Cell Death Discov."},{"key":"2709_CR73","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng, X. et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin. Cancer Res. 23, 4290\u20134300 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2709_CR74","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.canlet.2019.03.040","volume":"452","author":"D Wang","year":"2019","unstructured":"Wang, D. et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. Cancer Lett. 452, 244\u2013253 (2019).","journal-title":"Cancer Lett."},{"key":"2709_CR75","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2063225","volume":"11","author":"K Kos","year":"2022","unstructured":"Kos, K. et al. Tumor-associated macrophages promote intratumoral conversion of conventional CD4(+) T cells into regulatory T cells via PD-1 signalling. Oncoimmunology 11, 2063225 (2022).","journal-title":"Oncoimmunology"},{"key":"2709_CR76","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10585-007-9125-3","volume":"25","author":"RD Sanderson","year":"2008","unstructured":"Sanderson, R. D. & Yang, Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin. Exp. Metastasis 25, 149\u2013159 (2008).","journal-title":"Clin. Exp. Metastasis"},{"key":"2709_CR77","doi-asserted-by":"publisher","first-page":"28693","DOI":"10.18632\/oncotarget.4981","volume":"6","author":"MR Akl","year":"2015","unstructured":"Akl, M. R. et al. Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget 6, 28693\u201328715 (2015).","journal-title":"Oncotarget"},{"key":"2709_CR78","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1016\/j.csbj.2022.07.008","volume":"20","author":"AK Agrahari","year":"2022","unstructured":"Agrahari, A. K., Dikshit, M. & Asthana, S. Crystallographic mining of ASK1 regulators to unravel the intricate PPI interfaces for the discovery of small molecule. Comput. Struct. Biotechnol. J. 20, 3734\u20133754 (2022).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"2709_CR79","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bbrc.2015.06.078","volume":"464","author":"H Kim","year":"2015","unstructured":"Kim, H. et al. Cyclophilin A regulates JNK\/p38-MAPK signaling through its physical interaction with ASK1. Biochem. Biophys. Res. Commun. 464, 112\u2013117 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2709_CR80","doi-asserted-by":"crossref","unstructured":"Garcia-Ortiz, A. et al. The role of tumor microenvironment in multiple myeloma development and progression. Cancers 13, 217 (2021).","DOI":"10.3390\/cancers13020217"},{"key":"2709_CR81","doi-asserted-by":"publisher","first-page":"341430","DOI":"10.1155\/2015\/341430","volume":"2015","author":"WC Yang","year":"2015","unstructured":"Yang, W. C. & Lin, S. F. Mechanisms of drug resistance in relapse and refractory multiple myeloma. Biomed. Res. Int. 2015, 341430 (2015).","journal-title":"Biomed. Res. Int."},{"key":"2709_CR82","doi-asserted-by":"crossref","unstructured":"Sun, J. et al. IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma. Leukemia 38, 2355\u20132365 (2024).","DOI":"10.1038\/s41375-024-02391-8"},{"key":"2709_CR83","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1182\/blood.2024025275","volume":"143","author":"AK Azab","year":"2024","unstructured":"Azab, A. K. et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113:4341-4351. Blood 143, 2673 (2024).","journal-title":"Blood"},{"key":"2709_CR84","doi-asserted-by":"publisher","first-page":"518","DOI":"10.7150\/jca.9266","volume":"5","author":"A Jurczyszyn","year":"2014","unstructured":"Jurczyszyn, A. et al. HGF, sIL-6R and TGF-beta1 play a significant role in the progression of multiple myeloma. J. Cancer 5, 518\u2013524 (2014).","journal-title":"J. Cancer"},{"key":"2709_CR85","doi-asserted-by":"crossref","unstructured":"Yu, M., Zhou, V., Pisano, M. D., Janz, S. & Cui, X. Changes in the immune microenvironment during plasma cell tumor development in the IL6Myc mouse model of human multiple myeloma. Exp. Cell Res. 442, 114273 (2024).","DOI":"10.1016\/j.yexcr.2024.114273"},{"key":"2709_CR86","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","volume":"29","author":"M Larrayoz","year":"2023","unstructured":"Larrayoz, M. et al. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat. Med. 29, 632\u2013645 (2023).","journal-title":"Nat. Med."},{"key":"2709_CR87","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.canlet.2015.11.028","volume":"380","author":"JM Bouyssou","year":"2016","unstructured":"Bouyssou, J. M., Ghobrial, I. M. & Roccaro, A. M. Targeting SDF-1 in multiple myeloma tumor microenvironment. Cancer Lett. 380, 315\u2013318 (2016).","journal-title":"Cancer Lett."},{"key":"2709_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07038-1","volume":"15","author":"F Colombo","year":"2024","unstructured":"Colombo, F. et al. In vitro models of the crosstalk between multiple myeloma and stromal cells recapitulate the mild NF-kappaB activation observed in vivo. Cell Death Dis. 15, 731 (2024).","journal-title":"Cell Death Dis."},{"key":"2709_CR89","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-021-01038-w","volume":"14","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma. J. Hematol. Oncol. 14, 29 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2709_CR90","doi-asserted-by":"crossref","unstructured":"Ria, R. & Vacca, A. Bone marrow stromal cells-induced drug resistance in multiple myeloma. Int. J. Mol. Sci. 21, 613 (2020).","DOI":"10.3390\/ijms21020613"},{"key":"2709_CR91","doi-asserted-by":"crossref","unstructured":"Kwantwi, L. B. & Tandoh, T. Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: implications for cancer-associated therapies and tumor progression. Clin. Transl. Oncol. 27, 1398\u20131405 (2025).","DOI":"10.1007\/s12094-024-03723-x"},{"key":"2709_CR92","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.clml.2021.06.003","volume":"21","author":"LL George","year":"2021","unstructured":"George, L. L. et al. Emerging targets and cellular therapy for relapsed refractory multiple myeloma: a systematic review. Clin. Lymphoma Myeloma Leuk. 21, 741\u2013751 (2021).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2709_CR93","doi-asserted-by":"crossref","unstructured":"Radhakrishnan, V., Golla, U. & Kudva, A. K. Role of immune cells and immunotherapy in multiple myeloma. Life 14, 461 (2024).","DOI":"10.3390\/life14040461"},{"key":"2709_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.533","volume":"8","author":"J Chen","year":"2017","unstructured":"Chen, J. et al. BAFF is involved in macrophage-induced bortezomib resistance in myeloma. Cell Death Dis. 8, e3161 (2017).","journal-title":"Cell Death Dis."},{"key":"2709_CR95","first-page":"2606","volume":"109","author":"HM Sabol","year":"2024","unstructured":"Sabol, H. M. et al. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica 109, 2606\u20132618 (2024).","journal-title":"Haematologica"},{"key":"2709_CR96","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1182\/blood.2023022049","volume":"142","author":"E De Bruyne","year":"2023","unstructured":"De Bruyne, E. et al. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 2010;115(12):2430-2440. Blood 142, 1027 (2023).","journal-title":"Blood"},{"key":"2709_CR97","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.exphem.2010.06.012","volume":"38","author":"Y Cao","year":"2010","unstructured":"Cao, Y. et al. The cytokine\/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp. Hematol. 38, 860\u2013867 (2010).","journal-title":"Exp. Hematol."},{"key":"2709_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.775349","volume":"11","author":"AC Rapraeger","year":"2021","unstructured":"Rapraeger, A. C. Syndecans and their synstatins: targeting an organizer of receptor tyrosine kinase signaling at the cell-matrix interface. Front. Oncol. 11, 775349 (2021).","journal-title":"Front. Oncol."},{"key":"2709_CR99","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1242\/jcs.067645","volume":"123","author":"DM Beauvais","year":"2010","unstructured":"Beauvais, D. M. & Rapraeger, A. C. Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. J. Cell Sci. 123, 3796\u20133807 (2010).","journal-title":"J. Cell Sci."},{"key":"2709_CR100","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0014-5793(98)00310-X","volume":"426","author":"JM Dore","year":"1998","unstructured":"Dore, J. M., Morard, F., Vita, N. & Wijdenes, J. Identification and location on syndecan-1 core protein of the epitopes of B-B2 and B-B4 monoclonal antibodies. FEBS Lett. 426, 67\u201370 (1998).","journal-title":"FEBS Lett."},{"key":"2709_CR101","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.ejca.2012.12.019","volume":"49","author":"P Orecchia","year":"2013","unstructured":"Orecchia, P. et al. A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. Eur. J. Cancer 49, 2022\u20132033 (2013).","journal-title":"Eur. J. Cancer"},{"key":"2709_CR102","doi-asserted-by":"publisher","first-page":"37426","DOI":"10.18632\/oncotarget.6055","volume":"6","author":"P Orecchia","year":"2015","unstructured":"Orecchia, P. et al. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. Oncotarget 6, 37426\u201337442 (2015).","journal-title":"Oncotarget"},{"key":"2709_CR103","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","volume":"19","author":"S Jagannath","year":"2019","unstructured":"Jagannath, S. et al. Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and\/or refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 19, 372\u2013380 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2709_CR104","doi-asserted-by":"publisher","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","volume":"8","author":"KR Kelly","year":"2021","unstructured":"Kelly, K. R. et al. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1\/2a study. Lancet Haematol. 8, e794\u2013e807 (2021).","journal-title":"Lancet Haematol."},{"key":"2709_CR105","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s13277-012-0362-y","volume":"33","author":"C Rousseau","year":"2012","unstructured":"Rousseau, C. et al. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour Biol. 33, 679\u2013688 (2012).","journal-title":"Tumour Biol."},{"key":"2709_CR106","unstructured":"Thul, P. J. et al. A subcellular map of the human proteome. Science 356, eaal3321 (2017)."},{"key":"2709_CR107","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0092-8674(02)01079-6","volume":"111","author":"Q Li","year":"2002","unstructured":"Li, Q., Park, P. W., Wilson, C. L. & Parks, W. C. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111, 635\u2013646 (2002).","journal-title":"Cell"},{"key":"2709_CR108","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Therapeutic peptides: current applications and future directions. Signal Transduct. Target. Ther. 7, 48 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2709_CR109","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"DJ Craik","year":"2013","unstructured":"Craik, D. J., Fairlie, D. P., Liras, S. & Price, D. The future of peptide-based drugs. Chem. Biol. Drug Des. 81, 136\u2013147 (2013).","journal-title":"Chem. Biol. Drug Des."},{"key":"2709_CR110","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejmech.2018.02.057","volume":"149","author":"DN Reddy","year":"2018","unstructured":"Reddy, D. N. et al. Design, synthesis, and biological evaluation of stable beta(6.3)-Helices: discovery of non-hemolytic antibacterial peptides. Eur. J. Med. Chem. 149, 193\u2013210 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"2709_CR111","doi-asserted-by":"crossref","unstructured":"Dima, D. et al. Multiple myeloma therapy: emerging trends and challenges. Cancers 14, 4082 (2022).","DOI":"10.3390\/cancers14174082"},{"key":"2709_CR112","doi-asserted-by":"crossref","unstructured":"Papadimitriou, K. et al. Deep phenotyping reveals distinct immune signatures correlating with prognostication, treatment responses, and MRD status in multiple myeloma. Cancers 12, 3245 (2020).","DOI":"10.3390\/cancers12113245"},{"key":"2709_CR113","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1038\/sj.onc.1206919","volume":"22","author":"T Hideshima","year":"2003","unstructured":"Hideshima, T. et al. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene 22, 8797\u20138801 (2003).","journal-title":"Oncogene"},{"key":"2709_CR114","doi-asserted-by":"publisher","first-page":"17593","DOI":"10.1074\/jbc.C300076200","volume":"278","author":"D Chauhan","year":"2003","unstructured":"Chauhan, D. et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 278, 17593\u201317596 (2003).","journal-title":"J. Biol. Chem."},{"key":"2709_CR115","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907\u20134916 (2006).","journal-title":"Blood"},{"key":"2709_CR116","doi-asserted-by":"publisher","first-page":"745","DOI":"10.4161\/cbt.5.7.2971","volume":"5","author":"A Fribley","year":"2006","unstructured":"Fribley, A. & Wang, C. Y. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol. Ther. 5, 745\u2013748 (2006).","journal-title":"Cancer Biol. Ther."},{"key":"2709_CR117","doi-asserted-by":"publisher","first-page":"9695","DOI":"10.1128\/MCB.24.22.9695-9704.2004","volume":"24","author":"A Fribley","year":"2004","unstructured":"Fribley, A., Zeng, Q. & Wang, C. Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell. Biol. 24, 9695\u20139704 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"2709_CR118","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41375-019-0519-4","volume":"34","author":"I Akhmetzyanova","year":"2020","unstructured":"Akhmetzyanova, I. et al. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. Leukemia 34, 245\u2013256 (2020).","journal-title":"Leukemia"},{"key":"2709_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.711980","volume":"12","author":"SY Yang","year":"2021","unstructured":"Yang, S. Y. et al. Characterization of organ-specific regulatory B cells using single-cell RNA sequencing. Front. Immunol. 12, 711980 (2021).","journal-title":"Front. Immunol."},{"key":"2709_CR120","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","volume":"10","author":"M Orecchioni","year":"2019","unstructured":"Orecchioni, M., Ghosheh, Y., Pramod, A. B. & Ley, K. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front. Immunol. 10, 1084 (2019).","journal-title":"Front. Immunol."},{"key":"2709_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103349","volume":"24","author":"T Welte","year":"2021","unstructured":"Welte, T. et al. A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells. iScience 24, 103349 (2021).","journal-title":"iScience"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02709-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02709-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02709-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:03:04Z","timestamp":1778544184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02709-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2709"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02709-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}